Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
Skyline Therapeutics (skytx.com) is the corporate website of Skyline Therapeutics (Shanghai) Co., Ltd., positioned as an “integrated gene therapy company.” Based on the site content, the company focuses on the research and development of gene and cell therapies for rare and severe diseases, with its core technical approach centered on adeno-associated virus (AAV) vectors. It belongs to the healthcare and biopharmaceutical R&D sector, rather than being a general online medical service or pharmaceutical sales platform.
The website primarily serves corporate presentation and information disclosure purposes, including company introductions, science and programs, technology and manufacturing, partnerships, news, careers, and contact information. It highlights end-to-end AAV capabilities: from novel capsid discovery, vector engineering, in vivo pharmacology, and clinical development to analytical/process development, CMC, and GMP manufacturing. The capDRIVE® platform is its core technology label, used to screen novel AAV capsids with specific characteristics. The news section discloses progress such as the presentation of SKG1108, a gene therapy for retinitis pigmentosa, at ASGCT and its FDA Orphan Drug Designation.
The website does not publicly list product prices, service packages, or patient-facing fee information. Given the nature of its business, Skyline is more likely to commercialize through drug R&D, licensing partnerships, clinical translation, technology platform collaborations, or strategic partnerships, rather than through an online order-based service model.
Its strengths are its professional positioning, relatively complete AAV platform capability chain, Chinese and English pages, filing information, and fairly standardized legal and privacy policies. For pharmaceutical companies, research institutions, investors, and job candidates, the site provides a quick way to understand the company’s technical direction and some R&D progress. The drawbacks are that the website offers limited depth of disclosure and lacks a complete pipeline chart, clinical stages, indication strategy, key trial data, and detailed partnership cases. Ordinary patients also cannot obtain medical advice through the site, which explicitly states that its content does not constitute medical advice.
It is suitable for researchers, BD partners, pharmaceutical investors, regulatory/clinical development professionals, and job seekers interested in gene therapy, AAV vectors, and therapies for inherited eye diseases. It is not suitable as a channel for patients to self-diagnose, purchase medication, or obtain personalized treatment advice.
The website has Shanghai ICP and public security filings, as well as a Chinese-language entry point, so it should be directly accessible from mainland China. Overall, this is a professional biopharmaceutical corporate website with good credibility and compliance presentation, though there is still room to improve public transparency.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on skytx.com official site.
skytx.com is an China Health provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of China direct-connect friendly. Click "Visit Official Site" to reach skytx.com directly.